Advertisement
PCSA vs RADX
Which Stock Would AI Choose? Processa Pharmaceuticals (PCSA) vs. Radiopharm Theranostics (RADX) Stock Comparison
Key Takeaways
- Both PCSA and RADX are clinical-stage biopharmaceutical companies with pre-revenue business models, making this comparison most relevant to investors comfortable with early-stage, high-risk drug developers.
- Tickeron AI Verdict: RADX is currently favored on the strength of a clearer near-term catalyst path, including U.S. FDA alignment on a pivotal Phase 3 trial and positive clinical data.
- Processa Pharmaceuticals is pivoting around a newly acquired central nervous system (CNS) asset following a transformative financing, while Radiopharm Theranostics is advancing a diversified oncology radiopharmaceutical pipeline.
- Relative performance diverged in recent months, with RADX carrying more visible clinical and strategic milestones even as both stocks trade well below their 52-week highs.
- For more detail, explore PCSA Major News and PCSA Today's Price Move, as well as RADX Major News and RADX Today's Price Move.
- To see how automated systems are positioning across these and other tickers, explore Trending AI Robots.
Introduction
Both PCSA and RADX operate at the clinical-stage end of the biotechnology spectrum, where share prices are driven less by earnings and more by trial readouts, regulatory milestones, and financing events. Comparing the two offers a useful case study in how distinct development strategies, pipelines, and capital structures shape relative performance and market positioning. This comparison is most relevant to growth-oriented and event-driven traders and investors who are willing to weigh binary clinical catalysts against significant downside risk. It also suits readers evaluating two small-cap names with very different geographic footprints, therapeutic focuses, and momentum profiles.
PCSA Overview and Recent Performance
PCSA, or Processa Pharmaceuticals, is a U.S.-based clinical-stage biopharmaceutical company historically focused on oncology. In recent weeks the company has emphasized a strategic repositioning following its acquisition of Vidya Therapeutics, which brought in VT-7208, a central nervous system (CNS)-penetrant Bruton's tyrosine kinase (BTK) inhibitor being developed for conditions including food allergy and multiple sclerosis. The deal was paired with a substantial private placement, materially strengthening the company's cash position and extending its operating runway.
Recent stock behavior has reflected both the post-acquisition reset and lingering micro-cap volatility. Processa shares have rebounded from autumn lows but remain far below their 52-week high, with the company carrying a market capitalization in the low single-digit millions. Sentiment has been shaped by leadership appointments announced in recent weeks and by a pipeline transition, while its legacy NGC-Cap oncology program has seen its Phase 2 trial placed on hold. As a pre-revenue developer, PCSA remains sensitive to dilution and clinical-execution risk.
RADX Overview and Recent Performance
RADX, or Radiopharm Theranostics, is an Australian-headquartered clinical-stage radiopharmaceutical company developing diagnostic and therapeutic oncology agents. Its lead asset, RAD101, is a positron emission tomography (PET) imaging agent for detecting brain metastases, which reported 93% concordance with magnetic resonance imaging (MRI) in a Phase 2b trial. In recent weeks the company announced alignment with the U.S. Food and Drug Administration (FDA) on a single pivotal Phase 3 trial, with study initiation targeted for early 2027.
The stock has faced sustained downward pressure over the past year and has traded near the lower end of its 52-week range, partly reflecting ongoing capital raises and dilution. Radiopharm has raised funds through U.S. and Australian offerings to advance its pipeline, and it attracted a disclosed stake from Lantheus Holdings. Analyst coverage includes a Buy rating, and the company maintains a diversified early-stage portfolio. Like PCSA, RADX is pre-revenue and unprofitable, making cash runway and clinical progress central to its market positioning.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, yet only those judged most suitable for current market conditions earn a place in this featured section. These bots vary considerably in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, allowing users to compare approaches rather than relying on a one-size-fits-all system. For traders seeking a data-driven lens on names such as PCSA and RADX, reviewing the Trending AI Robots page can provide additional, continuously updated perspective on relative momentum and positioning.
Head-to-Head Comparison
The two companies differ most sharply in their strategic focus and catalyst timelines. PCSA is in the early stages of integrating an acquired CNS-focused BTK inhibitor platform, meaning its value narrative is largely forward-looking and dependent on proof-of-concept data that may not arrive until later in the decade. RADX, by contrast, has a lead imaging asset already through Phase 2b with FDA alignment on a pivotal trial, giving it a comparatively nearer-term, more defined regulatory path.
On capital structure, both names carry dilution risk, but the mechanisms differ. Processa secured a large private placement that strengthened its balance sheet, while Radiopharm has relied on repeated equity raises and warrants, contributing to a heavily diluted share count and a stock trading near historic lows. Sector exposure also differs: Processa spans oncology and emerging CNS programs, while Radiopharm is concentrated in radiopharmaceuticals, a specialized but strategically appealing niche that has drawn interest from larger peers. In terms of market sentiment, RADX benefits from analyst coverage and a strategic institutional stake, whereas PCSA faces thinner coverage and greater uncertainty around its post-acquisition direction.
Tickeron AI Verdict
Based on observable factors such as catalyst clarity, trend consistency, and relative positioning, Tickeron's AI would currently lean toward RADX. The company's alignment with the FDA on a pivotal Phase 3 trial, positive Phase 2b data, and presence of institutional interest provide a more concrete near-term roadmap than the earlier-stage repositioning underway at PCSA. That said, the verdict is probabilistic rather than definitive: Radiopharm's persistent dilution and weak price trend introduce meaningful risk, while Processa's strengthened cash position could support a re-rating if its new platform executes. Investors should weigh these trade-offs against their own risk tolerance and time horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCSA is a Hold and RADX is a Hold.
PCSA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PCSA turned positive on October 12, 2026. Looking at past instances where PCSA's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCSA's RSI Oscillator exited the oversold zone, 40 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCSA as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
PCSA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCSA crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCSA advanced for three days, in 183 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 49 of 57 cases where PCSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 33 cases where PCSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-16.725) is normal, around the industry mean (3.498). P/E Ratio (2.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PCSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for RADX turns negative, indicating new downward trend
RADX saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 42 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Oscillator exited the oversold zone, 6 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 10 of 16 cases over the following month. The odds of a continued upward trend are 62%.
Following a +10.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.263) is normal, around the industry mean (3.498). P/E Ratio (-0.051) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PCSA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | |
P/E GROWTH RATING 1..100 | 63 | |
SEASONALITY SCORE 1..100 | 1 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| PCSA | RADX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 84% | 6 days ago 80% |
| Declines ODDS (%) | 10 days ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCSA’s FA Score shows that 1 FA rating(s) are green while RADX’s FA Score has 1 green FA rating(s).
- PCSA’s FA Score: 1 green, 4 red.
- RADX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCSA’s TA Score shows that 7 TA indicator(s) are bullish while RADX’s TA Score has 4 bullish TA indicator(s).
- PCSA’s TA Score: 7 bullish, 2 bearish.
- RADX’s TA Score: 4 bullish, 3 bearish.
Price Growth
PCSA (@Biotechnology) experienced а -3.61% price change this week, while RADX (@Biotechnology) price change was -4.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
PCSA is expected to report earnings on Nov 12, 2026.
RADX is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PCSA and
Correlation & Price change
A.I.dvisor indicates that over the last year, PCSA has been loosely correlated with RADX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PCSA jumps, then RADX could also see price increases.
| Ticker / NAME | Correlation To PCSA | 1D Price Change % | ||
|---|---|---|---|---|
| PCSA | 100% | N/A | ||
| RADX - PCSA | 48% Loosely correlated | -2.35% | ||
| INO - PCSA | 38% Loosely correlated | +1.72% | ||
| ONCO - PCSA | 35% Loosely correlated | +8.36% | ||
| IBO - PCSA | 32% Poorly correlated | -6.93% | ||
| EDIT - PCSA | 28% Poorly correlated | -4.99% | ||
More | ||||
RADX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RADX has been loosely correlated with PCSA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RADX jumps, then PCSA could also see price increases.
| Ticker / NAME | Correlation To RADX | 1D Price Change % | ||
|---|---|---|---|---|
| RADX | 100% | -2.35% | ||
| PCSA - RADX | 49% Loosely correlated | N/A | ||
| ARTV - RADX | 44% Loosely correlated | +0.25% | ||
| VTGN - RADX | 33% Poorly correlated | +2.57% | ||
| CVKD - RADX | 31% Poorly correlated | +0.69% | ||
| FBIOP - RADX | 29% Poorly correlated | +0.64% | ||
More | ||||